United Kingdom
Add to My Companies | Give a Referral for this Company | Print this ProfileThe latest news, announcements and press releases from Cellular Origins.
Cytiva, a global life sciences leader, and Cellular Origins, a TTP company dedicated to advancing scalable and cost-effective cell and gene therapy (CGT) manufacturing, have entered into a collaboration designed to revolutionize the manufacture of cell therapies. By combining Cytiva’s automated Sefia platform with Cellular Origin’s automated robotic platform, Constellation, CGT manufacturers will be able to scale up production to industrial levels without changing the process used during discovery phases or clinical trials.
The two systems will interface seamlessly, providing complete digital interconnection, including quality control systems, fully remote digital controls, and analytics. Removing the need for manual intervention between and within CGT manufacturing steps will help drive new standards of automation and manufacturing productivities.
CAMBRIDGE, UK, 11 September 2024: Cellular Origins, a TTP Company, focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), today announced a collaboration with 3P innovation, a leading engineering company and supplier of automated fill-finish equipment. The partnership will integrate 3P innovation’s cryoFIL™ cryovial filling platform within Cellular Origins’ robotic system, Constellation™, expanding the system’s capabilities by enabling automated filling of cryovials within a closed and sterile environment.
3P innovation’s cryoFIL platform is designed to automate and streamline filling processes in cell and gene therapy workflows, incorporating the Company’s proven technology within a cGMP compliant robotic platform. Designed to provide reliable and repeatable liquid filling, cryoFIL’s automated workflow utilises a closed loop filling and 100% weight verification approach to ensure the maximum yield of manufactured therapies.
CAMBRIDGE, UK, 02 July 2024: Cellular Origins, a TTP Company, focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), today announced the acquisition of the ACTIA (Autologous Cell Therapy Industrial Automation) Platform IP, developed by Geoff Hodge whilst CEO of SOTIO Biotech US. The ACTIA Platform complements Cellular Origins’ existing approach and will accelerate and expand R&D efforts to further develop the Company’s robotic solution for automated cell therapy manufacturing, Constellation™.
Cambridge, UK, and St. Paul, MN, USA, 11 May 2023: Cellular Origins, a TTP Company focused on enabling scalable, cost-effective and efficient manufacture of cell and gene therapies (CGTs), has today announced a collaborative partnership with ScaleReady, a joint venture between Bio-Techne, Fresenius Kabi and Wilson Wolf that brings together process development expertise, tools and technologies for scalable CGT manufacturing. The partnership aims to automate portions of ScaleReady’s CGT manufacturing workflow by using Cellular Origin’s robotic system for sterile liquid transfer.
This is the News section of the company profile page for Cellular Origins on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.